Skip to main content
Europe gains first biosimilar to breast cancer drug Herceptin
3/12/2018

MSD launched Ontruzant, Europe's first biosimilar to Roche Holding's Herceptin, or trastuzumab, in the UK. The breast cancer treatment biosimilar was developed by Samsung Bioepsis.

Full Story: